European Journal of Clinical Pharmacology

, Volume 74, Issue 2, pp 245–246 | Cite as

Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer

  • A. Garrahy
  • A. M. Hannon
  • H. M. Zia-Ul-Hussnain
  • D. J. Williams
  • C. J. Thompson
Letter to the Editor
  • 79 Downloads

Notes

Acknowledgements

We thank Dr. Chris Boot (Newcastle upon Tyne) for the measurement of plasma copeptin.

Compliance with ethical standards

Conflict of interest

Professor Chris Thompson has received honoraria for lectures from Otsuka.

Dr. Aoife Garrahy, Dr. Anne Marie Hannon, Dr. Zia-Ul-Hussnain, and Professor David Williams have no potential conflicts of interest.

Supplementary material

228_2017_2363_MOESM1_ESM.docx (47 kb)
ESM 1 (DOCX 46 kb)

References

  1. 1.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355(20):2099–2112CrossRefPubMedGoogle Scholar
  2. 2.
    Salahudeen AK, Ali N, George M, Lahoti A, Palla S (2014) Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer 120(5):744–751CrossRefPubMedGoogle Scholar
  3. 3.
    Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J et al (2010) Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21(4):705–712CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • A. Garrahy
    • 1
  • A. M. Hannon
    • 1
  • H. M. Zia-Ul-Hussnain
    • 1
  • D. J. Williams
    • 2
  • C. J. Thompson
    • 1
  1. 1.Academic Department of EndocrinologyBeaumont Hospital and RCSI Medical SchoolDublinIreland
  2. 2.Department of Geriatric and Stroke MedicineBeaumont Hospital and RCSI Medical SchoolDublinIreland

Personalised recommendations